Company Profile
Immunocore Holdings plc Stock Price, News & Analysis
Company overview
Business overview
Immunocore Holdings plc is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Immunocore Holdings plc is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates.
Business Model Characteristics
Immunocore Holdings plc is a pipeline-led immunology story, so the market tends to track readouts, regulatory milestones, and how the company expands from one immune program to the next.
Position Within the Biotechnology Landscape
Compared with more mature peers, Immunocore Holdings plc sits close to the development side of the biotech landscape, where immunology data can change sentiment quickly.
Why the stock is moving
IMCR is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Immunocore's catalysts are tebentafusp expansion beyond uveal melanoma and combination work that can widen the immuno-oncology franchise. The key question is whether the platform can keep turning one approved asset into a broader growth story.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Source: Immunocore Holdings plc
- 02
Immunocore announces R&D leadership evolution
Source: Immunocore Holdings plc
- 03
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2026
Source: Immunocore Holdings plc
- 04
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Source: Immunocore Holdings plc
- 05
Immunocore to present at upcoming investor conferences
Source: Immunocore Holdings plc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.